Trends in Prescribing of Antipsychotic Medications for US Children


      To identify frequencies of prescribing for antipsychotics among all US children.


      Data were drawn from the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey, which are national samples of health care services rendered to the US population. Survey data were used to determine antipsychotic prescription frequencies for 2–18 year old US children from 1995–2002.


      During 1995–2002, there were 5 762 193 visits to health providers by US children during which an antipsychotic was prescribed. Almost one third (32.4%) of the prescriptions were associated with visits to nonmental health providers. Fifty-three percent of the prescriptions were for behavioral indications or affective disorders, conditions for which antipsychotics have not been carefully studied in children. The overall frequency of antipsychotic prescribing increased from 8.6 per 1000 US children in 1995–1996 to 39.4 per 1000 US children in 2001–2002 (rate ratio 4.89, 95% CI, 2.50-9.55). Across all age groups, increases for nonstudied indications were even more pronounced than increases for approved indications.


      The increase in frequencies of antipsychotic prescribing and the large number of children receiving antipsychotics each year reinforce the urgent need to conduct well-controlled studies of these medications in children.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Academic Pediatrics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Cooper W.O.
        • Hickson G.B.
        • Fuchs C.
        • et al.
        New users of antipsychotic medications among children enrolled in TennCare.
        Arch Pediatr Adolesc Med. 2004; 158: 753-759
        • Zito J.M.
        • Safer D.J.
        • Dosreis S.
        • et al.
        Psychotropic practice patterns for youth.
        Arch Pediatr Adolesc Med. 2003; 157: 17-25
        • Patel N.C.
        • Crismon M.L.
        • Hoagwood K.
        • et al.
        Trends in the use of typical and atypical antipsychotics in children and adolescents.
        J Am Acad Child Adolesc Psychiatry. 2005; 44: 548-556
        • Campbell M.
        • Rapoport J.L.
        • Simpson G.M.
        Antipsychotics in children and adolescents.
        J Am Acad Child Adolesc Psychiatry. 1999; 38: 537-545
        • Cortese L.
        • Pourcher-Bouchard E.
        • Williams R.
        Assessment and management of antipsychotic-induced adverse events.
        Can J Psychiatry. 1998; 43: 15S-20S
        • Ratzoni G.
        • Gothelf D.
        • Brand-Gothelf A.
        • et al.
        Weight gain associated with olanzapine and risperidone in adolescent patients.
        J Am Acad Child Adolesc Psychiatry. 2002; 41: 337-343
        • Buse J.B.
        • Cavazzoni P.
        • Hornbuckle K.
        • et al.
        A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States.
        J Clin Epidemiol. 2003; 56: 164-170
        • Gianfrancesco F.
        • Grogg A.
        • Mahmoud R.
        • et al.
        Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders.
        Clin Ther. 2003; 25: 1150-1171
        • Wieck A.
        • Haddad P.M.
        Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences. Selective literature review.
        Br J Psychiatry. 2003; 182: 199-204
        • Wudarsky M.
        • Nicolson R.
        • Hamburger S.D.
        • et al.
        Elevated prolactin in pediatric patients on typical and atypical antipsychotics.
        J Child Adolesc Psychopharmacol. 1999; 9: 239-245
        • Jordan M.P.
        Ziprasidone-associated galactorrhea in a female teenager.
        J Am Acad Child Adolesc Psychiatry. 2003; 42: 4-5
        • Safer D.J.
        A comparison of risperidone-induced weight gain across the age span.
        J Clin Psychopharmacol. 2004; 24: 429-436
        • Patel N.C.
        • Kistler J.S.
        • James E.B.
        • Crismon M.L.
        A retrospective analysis of the short-term effects of olanzapine and quetiapine on weight and body mass index in children and adolescents.
        Pharmacotherapy. 2004; 24: 824-830
        • Blair J.
        • Scahill L.
        • State M.
        • Martin A.
        Electrocardiographic changes in children and adolescents treated with ziprasidone.
        J Am Acad Child Adolesc Psychiatry. 2005; 44: 73-79
        • Findling R.L.
        • McNamara N.K.
        • Branicky L.A.
        • et al.
        A double-blind pilot study of risperidone in the treatment of conduct disorder.
        J Am Acad Child Adolesc Psychiatry. 2000; 39: 509-516
        • Gerardin P.
        • Cohen D.
        • Mazet P.
        • Flament M.F.
        Drug treatment of conduct disorder in young people.
        Eur Neuropsychopharmacol. 2002; 12: 361-370
        • Cheng-Shannon J.
        • McGough J.J.
        • Pataki C.
        • McCracken J.T.
        Second-generation antipsychotic medications in children and adolescents.
        J Child Adolesc Psychopharmacol. 2004; 14: 372-394
        • Vitiello B.
        Psychopharmacology for young children.
        Pediatrics. 2001; 108: 983-989
        • Safer D.J.
        • Zito J.M.
        • Dosreis S.
        Concomitant psychotropic medication for youths.
        Am J Psychiatry. 2003; 160: 438-449
      1. National Center for Health Statistics.National Health Care Survey.Available at January 17, 2005

      2. US Bureau of the Census. US Census Bureau Population Estimates.

        • Cochran W.
        Sampling Techniques. 3rd ed. John Wiley & Sons, New York, NY1977
        • Casella G.
        • Berger R.L.
        Statistical Inference. 2nd ed. Duxbury Press, Duxbury, Calif2002
        • Kendell R.E.
        • Malcolm D.E.
        • Adams W.
        The problem of detecting changes in the incidence of schizophrenia.
        Br J Psychiatry. 1993; 162: 212-218
        • Morensen P.
        Schizophrenia and society.
        in: Mallarkey G. Managing Schizophrenia. Adis International Publications, Kwai Chung, Hong Kong2000: 1-8
        • Zito J.M.
        • Safer D.J.
        • Dosreis S.
        • et al.
        Trends in the prescribing of psychotropic medications to preschoolers.
        JAMA. 2000; 283: 1025-1030
        • Snyder R.
        • Turgay A.
        • Aman M.
        • et al.
        Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs.
        J Am Acad Child Adolesc Psychiatry. 2002; 41: 1026-1036
        • Van B.M.
        • De T.C.
        Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning.
        J Child Adolesc Psychopharmacol. 2001; 11: 5-13
        • McCracken J.T.
        • McGough J.
        • Shah B.
        • et al.
        Risperidone in children with autism and serious behavioral problems.
        N Engl J Med. 2002; 347: 314-321
        • Malone R.P.
        • Maislin G.
        • Choudhury M.S.
        • et al.
        Risperidone treatment in children and adolescents with autism.
        J Am Acad Child Adolesc Psychiatry. 2002; 41: 140-147
        • Masi G.
        • Cosenza A.
        • Mucci M.
        • Brovedani P.
        Open trial of risperidone in 24 young children with pervasive developmental disorders.
        J Am Acad Child Adolesc Psychiatry. 2001; 40: 1206-1214